Quercetin’s Anti-Plaque Powers Are Useless Without Fiber: Microbiome "Hand-Off" Revealed

In an interesting revelation for longevity biohackers and supplement users, researchers have demonstrated that the popular flavonoid quercetin is functionally inert against atherosclerosis unless accompanied by a specific diet matrix: high-fiber (microbiota-accessible carbohydrates, or MACs).

Using a mouse model of atherosclerosis, the team discovered that quercetin supplementation failed to reduce plaque burden in animals fed a low-fiber diet, despite equal dosage. The protective effect was only unlocked when quercetin was paired with a high-MAC diet, leading to a significant reduction in aortic sinus plaque area and inflammation. Crucially, this benefit was completely abolished in germ-free mice, proving that the host’s own metabolism is insufficient to activate quercetin’s cardiovascular benefits.

The study identifies a “metabolic hand-off” where gut bacteria—specifically enriched families like Eggerthellaceae—ferment the fiber and quercetin together to produce potent bioactive metabolites, such as protocatechuic acid and benzoylglutamic acid. These specific downstream compounds, rather than quercetin itself, were strongly correlated with reduced arterial plaque. This research fundamentally challenges the “pill-only” approach to supplementation, suggesting that without the prebiotic substrate of a fiber-rich diet, expensive flavonoid regimens may be biologically useless for cardiovascular protection.

Source:
Open Access Paper: Gut microbiota and diet matrix modulate the effects of the flavonoid quercetin on atherosclerosis

  • Institution: University of Wisconsin-Madison, USA.
  • Journal: npj Biofilms and Microbiomes.
  • Impact Evaluation: The impact score of this journal is 9.2 (JIF 2023), Therefore, this is a High impact journal within the specialized field of Microbiology and Biotechnology.

Lifespan Analysis

  • Lifespan Data: Not Applicable.
  • Assessment: This study was a disease-specific intervention (atherosclerosis) where animals were euthanized at a fixed time point (22 weeks of age) to assess plaque pathology. It did not evaluate maximum or median lifespan extension. Consequently, no comparison to reference “short-lived” control data is possible.

Mechanistic Deep Dive

The study delineates a clear Gut-Metabolite-Vascular Axis:

  1. The “Fiber-Bug” Requirement: Quercetin is lipophilic and usually absorbs better with fat. However, this study shows that for anti-atherogenic effects in a lower-fat context, the presence of MACs (fiber) is non-negotiable. The high-MAC diet promoted specific bacterial families (Eggerthellaceae, Ruminococcaceae) that were absent or suppressed in low-MAC/Germ-Free groups.
  2. Metabolite Production (The “Active Drug”): The authors found that quercetin itself (and its direct host conjugates like glucuronides) did not accumulate differently enough to explain the benefits. Instead, the bacterialcatabolites 3,4-dihydroxybenzoic acid (protocatechuic acid) and benzoylglutamic acid were significantly elevated only in the High-MAC + Quercetin group.
  3. Pathways Implicated:
  • Anti-Inflammatory: The study observed reduced macrophage accumulation (inflammation) and increased collagen (plaque stability) in the aortic root.
  • Mitochondrial/Metabolic: While not explicitly probing mTOR/AMPK, the accumulation of protocatechuic acid is notable. This compound has previously been linked to inhibiting VSMC proliferation and reducing oxidative stress, key drivers of arterial aging.
  1. No Lipid Effect: Surprisingly, quercetin did not improve plasma cholesterol or triglyceride profiles in any group. The protection was purely vascular/inflammatory, mediated by these specific phenolic acids.

Novelty

  • Diet Matrix Dependency: This is the first definitive evidence that fiber (MACs) acts as a “permissive switch” for quercetin’s cardiovascular efficacy. Previous assumptions that quercetin works solely via antioxidant properties or direct absorption are challenged.
  • Identification of “Ghost” Metabolites: The study highlights benzoylglutamic acid as a novel potential therapeutic marker for atherosclerosis, which was previously unexplored in this context.
  • Microbiome Specificity: It pinpoints Eggerthellaceae as a key responder to the Quercetin+Fiber combo, moving beyond generic “diversity” claims.

Critical Limitations

  • Translational Uncertainty (Mouse Model): The ApoE KO mouse is a hyper-lipidemic model driven by genetic modification. While useful for atherosclerosis, it does not perfectly mimic human vascular aging or spontaneous plaque rupture.
  • Sex Bias: The study used only male mice. Given the known sexual dimorphism in cardiovascular disease and microbiome composition, these findings cannot be automatically extrapolated to females. [Confidence: High]
  • Short Duration: The intervention lasted only 16 weeks (from age 6 to 22 weeks). It does not address long-term safety or efficacy in older animals.
  • Correlative Mechanism: While the study proves gut bugs are necessary, the specific causal role of Eggerthellaceae or benzoylglutamic acid remains correlative. They did not re-colonize GF mice with only these bacteria or infuse the metabolites directly to prove they recapitulate the phenotype.
  • Missing Human Data: No human stool or serum analysis was performed to validate if this specific fiber-quercetin interaction holds true in human biology.
3 Likes

Waaaaiiiitt a minute!! Why am I just now learning querceitn is potentially good for heart disease!!!

Every time I trim my stack, I find a new one I should take!!!

2 Likes

The data is all in mice… so I think it’s a little early. I wouldn’t use this as a reason to take it… but something to consider if you’re using Quercetin as a senolytic (make sure your fiber intake is high when doing so?).

Based on the bibliography and citations within the provided text, the following papers are referenced to support the claim that quercetin (and its downstream metabolites) offers protection against atherosclerosis.

Direct Animal Intervention Studies

These studies utilize murine models (specifically ApoE-/- mice) to demonstrate quercetin’s efficacy in reducing plaque burden and inflammation.

Mechanistic Studies on Active Metabolites

Human Epidemiological Context

1 Like

It is important to note that this is a synthetic diet consisting of pure/semi-pure ingredients (e.g. casein) as opposed to the high-MAC diet which consists of whole ingredients (e.g., ground wheat, ground corn middlings, dehulled soybean meal etc.).

Dietary fiber in the high-MAC diet is derived from various plants, including ground wheat, ground corn, wheat middling, dehulled soybean meal, and corn gluten meal.

https://www.nature.com/articles/s41522-024-00626-1

3 Likes

When we were looking at supplement studies that added the supplement to rapamycin, paraphrasing Dr. Blagosklonny, rapamycin plus anything makes the anything look better.
I am convinced fiber supplementation is good, but I have never been a big fan of quercetin.
IMO: Probably the fiber is doing the heavy lifting.

3 Likes

Any reason to suspect that the same might be true of Fisetin? (yes, mice, yes males, but speaking from the mechanistic perspective…)

I can’t take Quercitin, but I can take high doses of Fisetin as senolytics.

2 Likes

Thats a definite “maybe” ;-). Here is what Gemini Pro has to say:

Executive Summary: Fisetin for Atherosclerosis

Verdict: Promising Pre-clinical Data; Zero Validated Human Evidence.

There is currently no direct clinical evidence (Level A or B) that fisetin supplementation prevents or reverses atherosclerosis in humans. However, strong pre-clinical data (Level D) in ApoE-/- mice and cell cultures suggests potent anti-atherogenic mechanisms, primarily through senolysis (clearing senescent “zombie” cells) and anti-inflammatory pathways .

Human trials are currently underway (e.g., NCT06133634 at University of Colorado), but results have not yet been published. Until then, any use for this specific indication is speculative and experimental.


The Evidence Hierarchy

  • Level A (Meta-Analyses): NONE.

  • Level B (Human RCTs): NONE COMPLETED.

    • Note: Two active trials are relevant:
      1. NCT06133634 (Active, Not Recruiting): “Fisetin to Improve Vascular Function in Older Adults.” Tests if fisetin improves endothelial function and reduces aortic stiffness.
      2. NCT06399809 (Recruiting): “Fisetin to Reduce Senescence… in PAD.” Focuses on Peripheral Artery Disease.
  • Level C (Observational): Weak/Indirect. High flavonoid intake is generally associated with better CV health, but isolating fisetin specifically is difficult due to its low concentration in most foods (strawberries are the main source).

  • Level D (Animal/Mechanistic): STRONG. Multiple studies confirm plaque reduction in mice.


Mechanistic Deep Dive (How it Should Work)

If the mouse data translates to humans, fisetin attacks atherosclerosis via three distinct vectors that distinguish it from standard statins or blood thinners:

  1. Senolysis (The “Zombie” Hunter):
  • Mechanism: Atherosclerotic plaques are loaded with senescent (aging) endothelial and smooth muscle cells that refuse to die. These cells secrete inflammatory junk (SASP) that destabilizes the plaque.
  • Data: Fisetin selectively induces apoptosis in these senescent cells, potentially stabilizing the plaque and improving vascular elasticity.
  • Key Paper: Fisetin is a senotherapeutic that extends healthspan and lifespan (EBioMedicine, 2018).
  1. PCSK9 & LOX-1 Inhibition (The Lipid Modulator):
  • Mechanism: Fisetin downregulates PCSK9 (a protein that degrades LDL receptors) and LOX-1 (the receptor that sucks oxidized LDL into macrophages to create foam cells).
  • Result: In mice, this dual action lowered circulating LDL and reduced the accumulation of lipids in the vessel wall.
  • Key Paper: Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 (2020).
  1. Anti-Calcification (The Softener):
  • Mechanism: Fisetin inhibits the p38 MAPK pathway, which drives the calcification (hardening) of vascular smooth muscle cells.
  • Result: Reduced calcium deposition in vessel walls in kidney disease models.
  • Key Paper: Fisetin ameliorates vascular smooth muscle cell calcification via DUSP1-dependent p38 MAPK inhibition (Aging, 2025).

Biohacker Translational Protocol (Experimental)

If you choose to experiment based on animal data, this is the extrapolated protocol.

  • Dosing (The “Hit-and-Run” Protocol):
    • Most senolytic experts (like the Mayo Clinic protocol) do not recommend daily chronic use.
    • Protocol: High dose for 2-3 consecutive days, followed by a long break (e.g., 2 weeks or 1 month off).
    • Rationale: You want to shock the senescent cells into apoptosis, then let the healthy tissue recover. Constant suppression might interfere with necessary growth signals.
    • Human Equivalent Dose: ~20 mg/kg is the standard trial dose. For a 75kg person, that is 1,500 mg/day.
  • Absorption Factor:
    • Fisetin has terrible bioavailability. It must be taken with fats (e.g., yogurt, olive oil) or in a lipid-formulation (e.g., liposomal) to ensure it enters the bloodstream.
  • Safety Flag:
    • CYP Interactions: Like quercetin, fisetin interacts with liver enzymes. Do not combine with blood thinners (Warfarin/Eliquis) without medical monitoring, as it may alter their metabolism.

Summary Table

Feature Status Notes
Plaque Reduction Mice Only Reduced plaque area and lipid content in ApoE-/- mice.
Lipid Lowering Mice Only Lowered LDL/Triglycerides via PCSK9 downregulation.
Vascular Stiffness Human Trial Ongoing Results pending (NCT06133634).
Safety Good generally recognized as safe (GRAS), but drug interactions exist.
Primary Mechanism Senolysis Clears aging cells from the vessel wall.
2 Likes

have you looked at Nattokinase? I read a very interesting article about a study done on Japanese. (I don’t have a reference for it though) But here is one on a china study: Frontiers | Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants Here is another good article on Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases - PMC I started using it about a month ago. I’m taking 15,000FU because my 10,000FU tabs are too hard to cut into thirds so I just split one in half. The study I read say that they found that 10800 was where they saw the most benefit. The big problem is it can increase the risk of bleeding so those taking blood thinners or bleeding disorders should probably avoid it unless their Dr ok’s it. other than that it has a good safety profile.

Thanks for mentioning this @sudiki. I don’t know much about nattonkinase because I stop reading when I get to the blood thinning aspect. Because I’m high risk for a heart attack, I take baby aspirin.

It seems the people who might benefit the most from nattokinase would already be taking baby aspirin.

This is me being naive and wondering why anyone chooses nattokinase instead? Are the bleeding risks lower, so perhaps those without CVD choose it over baby aspirin as prevention? I know a lot of smart people here take it.

1 Like

I take both: 12000UI/day nattokinase and 81mg/day aspirin.
BTW I take 1.5g/day Omega 3 (mostly EPA) too which is also a blood thinner.

1 Like

Baby aspirin doesn’t do what natto does. If you read the whole article(s) you will see what i mean. Basically, recent research has demonstrated that NK has potent fibrinolytic activity, antihypertensive, anti-atherosclerotic, and lipid-lowering, antiplatelet, and neuroprotective effects. It also is safer than low dose aspirin as the long-term use of aspirin comes with serious gastrointestinal (GI) side effects and bleeding. In a study comparing the antiplatelet effects of NK and aspirin, NK was shown to display excellent antiplatelet aggregation and antithrombotic activities in vitro and in vivo, inhibiting thromboxane B2 formation from collagen-activated platelets. Data suggests that NK could be a good candidate, without any obvious adverse effects, for the improvement of blood flow and possibly superior to aspirin.

I am NOT advocating anyone to quit their aspirin and use Natto instead w/o discussing this with your Dr.

1 Like

yes, I’m going to switch to 4000fu tabs once I use up my 10000fu supply. Taking three 4000fu will get me closer to the 10800fu that was used in some of the studies.

I take Neprinol AFD which is 30000fu Nattokinase and 90000fu Serrapeptase. I take asprin but not daily. It has a bunch of other good stuff in it too. I don’t think it’s a bleeding risk at all.

Blood clots are made of fibrin and plaque is made of fibrin, essentially blood clots. I don’t think this is dangerous at all, except possibly that fibrin helps your immune system some. It’s possible killing it all like I’m trying to do could increase my microbial burden. I’m less worried about that than I am about the heart disease.

1 Like

re: bleeding risk. I’m quoting from the studies done and also the Governments NIH website.

1 Like

From consumerlab on Quercetin. These are too many interactions for me…

Quercetin may increase the absorption, effects, and side effects of drugs that are substrates of the anion-transporting peptide OATP1B1. For example, in a study among ten healthy men who took 500 mg of quercetin daily for two weeks, followed by a single, 40 mg dose of pravastatin (Pravachol - a substrate of OATP1B1) absorption of the drug was increased by 24%, and the elimination half-life was prolonged by 14% (Br J Clin Pharmacol 2012). Other drugs that are OATP1B1 substrates include certain other statin drugs, such as rosuvastatin (Crestor), fluvastatin (Lescol), pitavastatin (Livalo) and atorvastatin (Lipitor), as well as conjugated estrogens, valsartan (Diovan), enalapril (Vasotec), methotrexate (Otrexup (PF), fexofenadine (Aller-ease, Allegra) and others (Kalliokoski, Br J Pharmacol 2009; Niemi, Br J Clin Pharmacol 2005;
Izumi, Drug Metab Dispos 2015).

Quercetin may inhibit the enzyme CYP2C9 (Rastogi, Phytother Res 2014), potentially increasing the effects of drugs that are metabolized by this enzyme. For example, a study among healthy adults showed that 500mg of quercetin taken twice dailv. for 10 days significantly increased the absorption of the nonsteroidal anti-inflammatory drug diclofenac (Voltaren, Flector), which is metabolized by CYP2C9 (Bedada, Phytother Res 2018). Other drugs that are metabolized by this enzyme include celecoxib (Celebrex), fluvastatin (Lescol), glipizide (Glucotrol), ibuprofen (Advil, Motrin), losartan (Cozaar), phenytoin (Dilantin), piroxicam (Feldene), tamoxifen (Nolvadex), and warfarin (Coumadin).

Quercetin also appears to inhibit the enzyme CYP2C8 and has been shown in animal studies to significantly increase blood levels of amiodarone (Pacerone, Cordarone, Nexterone), a drug metabolized mainly by CYP2C8 and one other enzyme and that is prescribed for certain types of fast or irregular heart rhythm (Ahmad, Eur Rev Med Pharmacol Sci 2023). This effect has not been documented in people, but because small differences in levels of amiodarone may significantly impact its effects and side effects, people who take this drug should consult with their physician before taking quercetin. Other drugs metabolized by this enzyme include dasabuvir (Exviera), enzalutamide (Xtandi), imatinib (Gleevec), loperamide (Immodium), paclitaxel (Taxol), repaglinide (Prandin), and others.

Quercetin may increase the activity of the enzyme CYP3A in the intestines, and therefore may decrease the effects of drugs metabolized by this enzyme. For example, in a small study among healthy adults, 500 mg of quercetin taken daily for 13 days significantly reduced the activity of the sedative midazolam (a single, 7.5 mg dose) taken on day 14 (Duan, J Clin Pharmacol 2012). Other drugs that are metabolized by this enzyme include statins such as atorvastatin (Lipitor), lovastatin (Mevacor, Altoprev) or simvastatin (Zocor), blood pressure-lowering drugs such as losartan (Cozaar), felodipine (Pendil) and amlodipine (Norvasc), anticoagulants such as apixaban (Eliquis) and rivaroxaban (Xarelto), calcium channel blockers such as diltiazem (Cardizem), nicardipine (Cardene IV), and verapamil (Verelan), sedatives/benzodiazepines such as diazepam…

1 Like

I saw this today, I am researching fermented foods…

Q. “I take Aspirin for heart health. Is Nattokinase safe to add?” Answer: Proceed with extreme caution. Nattokinase is a potent fibrinolytic. Combining it with Aspirin, Warfarin, or Plavix significantly increases bleeding risk. There are documented cases of hemorrhage when combining these agents. You must monitor coagulation markers (PT/INR) if attempting this combination, but avoidance is safer.

2 Likes

There are a number of study’s done on fermented foods, especially Kimchi, which I partake of nearly every day. I fell for it during my tours in Korea… kimchi has like anywhere from 9 to14 health benefits depending on what source you are reading.

1 Like

Including giving you stomach cancer.

1 Like

This comment caught me off guard since I eat two tablespoon of kimchi every day and have been doing so for a very long time. From what I have been reading, it seems likely that it’s the highly salted kimchi that was causing an increase in South Korea? I am not sure I would be too concerned.

https://www.mdlinx.com/article/have-you-heard-of-the-kimchi-cancer-epidemic/5cyjvknEhz1765yBhQfDXF

High levels of salt cause atrophic gastritis which leads to metaplasia, then dysplasia, and finally cancer. Correa cascade. H. Pylori is the other big risk factor, and infection rates are high in much of Asia.

1 Like